Immunogencity of HSA-L7/L12 (Brucella abortus ribosomal protein) in an animal model

Iranian Journal of Immunology

Volumn 6, Issue 1, 2009, Pages 12-21

  Pakzad, Iraj ^a   Rezaee, Abbas ^b   Rasaee, Mohammad Javad ^b   Tabbaraee, Bahman ^c   Delpisheh, Ali ^a  

^a ILAM UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TARBIAT MODARES UNIVERSITY   (Iran)

^c PASTEUR INSTITUTE OF IRAN   (Iran)

Author keywords

Brucella abortus; Fusion protein; Human serum albumin; L7 L12

Indexed keywords

BRUCELLA VACCINE; HUMAN SERUM ALBUMIN; HYBRID PROTEIN; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A ANTIBODY; RECOMBINANT HUMAN SERUM ALBUMIN L7 L12 FUSION PROTEIN; RECOMBINANT PROTEIN; RECOMBINANT RIBOSOME PROTEIN L7 L12; UNCLASSIFIED DRUG; BACTERIAL PROTEIN; IMMUNOGLOBULIN G; RIBOSOMAL PROTEIN L7 L12; RIBOSOMAL PROTEIN L7-L12; RIBOSOME PROTEIN; SERUM ALBUMIN;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIGEN SPECIFICITY; ARTICLE; BACTERIAL COUNT; BACTERIAL VIRULENCE; BRUCELLA ABORTUS; BRUCELLOSIS; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXPRESSION VECTOR; FEMALE; GENE AMPLIFICATION; GENETIC TRANSFORMATION; HUMORAL IMMUNITY; IMMUNOGENICITY; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MOLECULAR CLONING; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTECTION; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SACCHAROMYCES CEREVISIAE; SUPERNATANT; T LYMPHOCYTE ACTIVATION; VACCINE PRODUCTION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BLOOD; CYTOLOGY; GENE VECTOR; GENETICS; HUMAN; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MICROBIOLOGY; SPLEEN; T LYMPHOCYTE; VACCINATION;

ANIMALS; ANTIBODY FORMATION; BACTERIAL PROTEINS; BRUCELLA ABORTUS; BRUCELLOSIS; FEMALE; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MODELS, ANIMAL; RECOMBINANT FUSION PROTEINS; RIBOSOMAL PROTEINS; SACCHAROMYCES CEREVISIAE; SERUM ALBUMIN; SPLEEN; T-LYMPHOCYTES; VACCINATION;

EID: 67650394255     PISSN: 17351383     EISSN: 1735367X     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Godfroid J, Cloeckaert A, Liautard JP, Kohler S, Fretin D, Walravens K, et al. From the discovery of the Malta fever's agent to the discovery of a marine mammal reservoir, brucellosis has continuously been a re-emerging zoonosis. Vet Res. 2005; 36: 313-26.
2. Schurig GG, Sriranganathan N, Corbel MJ. Brucellosis vaccines: past, present and future. Vet Microbiol. 2002; 90: 479-96.
3. Moriyon I, Grillo MJ, Monreal D, Gonzalez D, Marin C, Lopez-Goni I, et al. Rough vaccines in animal brucellosis: structural and genetic basis and present status. Vet Res. 2004; 35: 1-38.
4. Oliveira SC, Splitter GA. Immunization of mice with recombinant L7/L12 ribosomal protein confers protection against Brucella abortus infection. Vaccine. 1996; 14:959-62.
5. Onate AA, Vemulapalli R, Andrews E, Schurig GG, Boyle S, Folch H. Vaccination with live Escherichia coli expressing Brucella abortus Cu/Zn superoxide dismutase protects mice against virulent B. abortus. Infect Immun. 1999; 67: 986-8.
6. Vemulapalli R, He Y, Cravero S, Sriranganathan N, Boyle SM, Schurig GG. Overexpression of protective antigen as a novel approach to enhance vaccine efficacy of Brucella abortus strain RB51. Infect Immun. 2000; 68: 3286-9.
7. Oliveira SC, Splitter GA. Subcloning and expression of the Brucella abortus L7/L12 ribosomal gene and T-lymphocyte recog-nition of the recombinant protein. Infect Immun. 1994; 62: 5201-4.
8. Kurar E, Splitter GA. Nucleic acid vaccination of Brucella abortus ribosomal L7/L12 gene elicits immune response. Vaccine. 1997; 15: 1851-7.
9. Baloglu S, Boyle SM, Vemulapalli R, Sriranganathan N, Schurig GG, Toth TE. Immune responses of mice to vaccinia virus recombinants expressing either Listeria monocytogenes partial listeriolysin or Brucella abortus ribosomal L7/L12 protein. Vet Microbiol. 2005;109: 11-7.
10. Pontes DS, Dorella FA, Ribeiro LA, Miyoshi A, Le Loir Y, Gruss A, et al. Induction of partial protection in mice after oral administration of Lactococcus lactis producing Brucella abortus L7/L12 antigen. J Drug Target. 2003; 11: 489-93.
11. Ribeiro LA, Azevedo V, Le Loir Y, Oliveira SC, Dieye Y, Piard JC, et al. Production and targeting of the Brucella abortus antigen L7/L12 in Lactococcus lactis: a first step towards food-grade live vaccines against brucellosis. Appl Environ Micro-biol. 2002; 68: 910-6.
12. Schirmbeck R, Kwissa M, Fissolo N, Elkholy S, Riedl P, Reimann J. Priming polyvalent immunity by DNA vaccines express-ing chimeric antigens with a stress protein-capturing, viral J-domain. FASEB J. 2002; 16: 1108-10.
13. Johnston D, Bystryn JC. Heterogeneous antibody response to polyvalent melanoma vaccines in syngeneic mice. Cancer Im-munol Immunother. 2005; 54: 345-50.
14. Huang L, Krieg AM, Eller N, Scott DE. Induction and regulation of Th1-inducing cytokines by bacterial DNA, lipopolysac-charide, and heat-inactivated bacteria. Infect Immun. 1999; 67: 6257-63.
15. David SA. The interaction of lipid A and lipopolysaccharide with human serum albumin. In: H.Brade, S.M.Opal, S.N.Vogel, and D.C.Morrison, (Editors). Endotoxins in health and disease. New York: Marcel Dekker; 1999. p. 413-22.
16. Kang HA, Choi ES, Hong WK, Kim JY, Ko SM, Sohn JH, et al. Proteolytic stability of recombinant human serum albumin secreted in the yeast Saccharomyces cerevisiae. Appl Microbiol Biotechnol. 2000; 53: 575-82.
17. Rezaee MA, Rezaee A, Moazzeni SM, Salmanian AH, Yasuda Y, Tochikubo K, et al. Expression of Escherichia coli heat-labile enterotoxin B subunit (LTB) in Saccharomyces cerevisiae. J Microbiol. 2005; 43: 354-60.
18. Wilson K. Preparation of genomic DNA from bacteria. Curr Protoc Mol Biol. 2001; Chapter 2: Unit 2 4.
19. Choi ES, Sohn JH, Rhee SK. Optimization of the expression system using galactose-inducible promoter for the production of anticoagulant hirudin in Saccharomyces cerevisiae. Appl Microbiol Biotechnol. 1994; 42: 587-94.
20. Zhan Y, Yang J, Cheers C. Cytokine response of T-cell subsets from Brucella abortus-infected mice to soluble Brucella pro-teins. Infect Immun. 1993; 61: 2841-7.
21. Winter AJ, Schurig GG, Boyle SM, Sriranganathan N, Bevins JS, Enright FM, et al. Protection of BALB/c mice against ho-mologous and heterologous species of Brucella by rough strain vaccines derived from Brucella melitensis and Brucella suis biovar 4. Am J Vet Res. 1996; 57: 677-83.
22. Cloeckaert A, Zygmunt MS, Bezard G, Dubray G. Purification and antigenic analysis of the major 25-kilodalton outer mem-brane protein of Brucella abortus. Res Microbiol. 1996; 147: 225-35.
23. Cloeckaert A, Vizcaino N, Paquet JY, Bowden RA, Elzer PH. Major outer membrane proteins of Brucella spp.: past, present and future. Vet Microbiol. 2002; 90: 229-47.
24. Ko J, Splitter GA. Molecular host-pathogen interaction in brucellosis: current understanding and future approaches to vaccine development for mice and humans. Clin Microbiol Rev. 2003; 16: 65-78.
25. Jacques M. Role of lipo-oligosaccharides and lipopolysaccharides in bacterial adherence. Trends Microbiol. 1996; 4: 408-9.
26. Oliveira SC, Splitter GA. CD8+ type 1 CD44hi CD45 RBlo T lymphocytes control intracellular Brucella abortus infection as demonstrated in major histocompatibility complex class I- and class II-deficient mice. Eur J Immunol. 1995; 25: 2551-7.
27. Onate AA, Cespedes S, Cabrera A, Rivers R, Gonzalez A, Munoz C, et al. A DNA vaccine encoding Cu,Zn superoxide dismu-tase of Brucella abortus induces protective immunity in BALB/c mice. Infect Immun. 2003; 71: 4857-61.